Search Results
The complement system in NMOSD and MG: A target for therapeutic benefit?
Upstream and Downstream Targeting of the Complement Pathway to Manage PNH
“Complement”ary Therapy in Autoimmune Disorders
Discussion of Neuromyelitis Optica Spectrum Disorder (NMOSD) and Transverse Myelitis (TM)
Treatment of MG | Prof. James Howard
Anti-Complement Therapeutics
Online Breakout Session: Approved Therapeutics
2022 Pre-RNDS | Neuromyelitis Optica Spectrum Disorder (NMOSD)
FDA Approval of Enspryng™ For Neuromyelitis Optica Spectrum Disorder (NMOSD)
Effects of Inebilizumab to Treat Myasthenia Gravis
Updates and Research and Clinical Trials for MG
Neuropathy and Neuromuscular Gene Panel Update
